Boston University

Health Research, Inc.

Jennifer E Beane-Ebel

Avrum Spira

Marc Elliott Lenburg

Jerome S Brody

Anna Tassinari

Mary E Reid

Sarah Mazzilli

The technology described herein is directed to methods of treating and diagnosing bronchial premalignant lesions, e.g. by determining the lesion subtype using one or more biomarkers described herein.

Methods related to bronchial premalignant lesion severity and progression

Disclosed herein are assays and methods for the identification of premalignant lesions, as well as methods of determining the likelihood that such premalignant lesions will progress to lung cancer. Also disclosed are methods and assays that are useful for monitoring the progression of premalignant lesions to lung cancer. The assays and methods disclosed herein provide minimally invasive means of accurately detecting and monitoring the presence or absence of premalignant lesions, thus providing novel insights into the earliest stages of lung cancer and facilitating early detection and early intervention.

Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions

The present invention provides methods for diagnosis and prognosis of lung cancer using expression analysis of one or more groups of genes, and a combination of expression analysis with bronchoscopy. The methods of the invention provide far superior detection accuracy for lung cancer when compared to any other currently available method for lung cancer diagnostic or prognosis. The invention also provides methods of diagnosis and prognosis of other lung diseases, particularly in individuals who are exposed to air pollutants, such as cigarette or cigar smoke, smog, asbestos and the like air contaminants or pollutants.

Diagnostic for lung disorders using class prediction

Growing community of inventors

Fort Collins, CO, United States of America

Jennifer E Beane-Ebel